Copyright
©The Author(s) 2022.
World J Gastrointest Surg. Nov 27, 2022; 14(11): 1260-1271
Published online Nov 27, 2022. doi: 10.4240/wjgs.v14.i11.1260
Published online Nov 27, 2022. doi: 10.4240/wjgs.v14.i11.1260
Table 7 Changes in platelet counts in group B (8-14 d of treatment)
| Baseline | Day 2 | Day 5 | Day 9 | Post-treatment | Change | |
| n | 38 | 20 | 29 | 26 | 38 | 38 |
| mean ± SD (× 109/L) | 45.42 ± 16.27 | 46.10 ± 14.34 | 60.79 ± 33.18 | 108.19 ± 65.18 | 133.85 ± 103.23 | 81.97 ± 90.29 |
| Median (× 109/L) | 43.00 | 43.50 | 55.00 | 96.00 | 95.00 | 55.00 |
| IQR (× 109/L) | 33.50-55.50 | 33.75-57.75 | 37.00-70.00 | 49.00-166.75 | 58.00-190.00 | 21.25-127.25 |
| Min, max (× 109/L) | 9.00, 80.00 | 25.00, 71.00 | 18.00, 170.00 | 28.00, 261.00 | 21.00, 489.00 | -27.00, 448.00 |
- Citation: Ding JN, Feng TT, Sun W, Cai XY, Zhang Y, Zhao WF. Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study. World J Gastrointest Surg 2022; 14(11): 1260-1271
- URL: https://www.wjgnet.com/1948-9366/full/v14/i11/1260.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v14.i11.1260